AC Immune SA chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.05
Dividend & YieldN/A$ (N/A)
Beta 0.53
Market capitalization 218.54M
Operating cash flow -73.99M
ESG Scores unknown

Company description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 846k 2.28M -1.98M 341k
Total Cashflows From Investing Activities -32.04M -66.89M 28.33M -53.66M
Net Borrowings -141k 50.06M -946k 22.95M
Total Cash From Financing Activities 109.38M 49.62M -803k 40.75M
Change To Operating Activities 268k 3.44M -2.57M 6.6M
Issuance Of Stock 111.53M 69k 243k 17.8M
Net Income -50.95M 45.44M -61.92M -73M
Change In Cash 32.09M 37.12M -32.69M -78.68M
Effect Of Exchange Rate -1.18M -826k -703k -70k
Total Cash From Operating Activities -44.08M 55.22M -59.52M -65.69M
Depreciation 961k 1.69M 1.97M 2.41M
Change To Account Receivables 698k -68k -25k -99k
Other Cashflows From Financing Activities -2.02M -510k -6k -6k
Change To Netincome 4.1M 2.43M 5.01M -1.94M
Capital Expenditures -1.86M -1.89M -1.71M -2.63M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -50.95M 45.44M -61.92M -72.99M
Net Income -50.95M 45.44M -61.92M -73M
Selling General Administrative 12.47M 16.06M 18.56M 17.91M
Gross Profit -37.37M 60.02M -44.06M -62.28M
Ebit -49.55M 44.54M -61.26M -79.01M
Operating Income -49.55M 44.54M -61.26M -79.01M
Interest Expense -334k -1.93M -184k -581k
Income Tax Expense 3k
Total Revenue 6.91M 110.46M 15.43M
Cost Of Revenue 44.28M 50.43M 59.49M 62.28M
Total Other Income ExpenseNet -1.3M 906k -661k 6.02M
Net Income From Continuing Ops -50.95M 45.44M -61.92M -73M
Net Income Applicable To Common Shares -50.95M 45.44M -61.92M -73M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 18.93M 26.81M 23.26M 29.46M
Total Stockholder Equity 177.62M 272.44M 215.48M 231.98M
Other Current Liabilities 351k 4.48M 306k 717k
Total Assets 196.56M 299.25M 238.74M 261.44M
Common Stock 1.35M 1.44M 1.54M 1.79M
Other Current Assets 10k 70k 20k
Retained Earnings -121.88M -75.52M -132.85M -200.94M
Treasury Stock -100k -124k
Cash 156.46M 193.59M 160.89M 82.22M
Total Current Liabilities 13.08M 17.51M 14.02M 20.03M
Other Stockholder Equity
Property, Plant, and Equipment 3.32M 6.17M 6.64M 8.03M
Total Current Assets 192.93M 292.77M 231.77M 202.63M
Net Tangible Assets 177.62M 272.44M 215.48M 181.56M
Net Receivables 4.09M 1.33M 1.9M 1.4M
Accounts Payable 1.98M 142k 2.18M 2M


Insider Transactions

Here are the insider transactions of stock shares related to AC Immune SA:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to AC Immune SA. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on AC Immune SA

Here is the result of two systematic investment strategies applied to AC Immune SA. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on AC Immune SA

The following chart shows the equity curve of the two systematic investment strategies applied to AC Immune SA:

AC Immune SA automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 8.05% on the backtest period.

Performance at glance

Performance

8.05 %

Latent gain

141.52 $

Invested capital

1756.95 $

Annualized return

1.96 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on AC Immune SA

This is the result of two momentum investment strategies applied to AC Immune SA. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on AC Immune SA

The following chart shows all the entries opened by the momentum investment system on AC Immune SA:

AC Immune SA momentum entries
  • The first momentum investment strategy would give 14.33% of return on AC Immune SA. That represents 752.31$ of latent gain with 5250.96$ of employed capital.
  • The second momentum investment strategy would give 9.01% of return on AC Immune SA. That represents 361.06$ of latent gain with 4007.62$ of employed capital.
Performance at glance (1Q Momentum)

Performance

14.33 %

Latent gain

752.31 $

Invested capital

5250.96 $

Annualized return

-0.39 %
Performance at glance (2Q Momentum)

Performance

9.01 %

Latent gain

361.06 $

Invested capital

4007.62 $

Annualized return

2.49 %

Momentum equity curve on AC Immune SA

The following chart shows the equity curve of the two momentum strategies applied to AC Immune SA:

AC Immune SA momentum equity

Note: the dividends potentially given by AC Immune SA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on AC Immune SA

The following chart shows the employed capital evolution of the two momentum strategies on AC Immune SA since the beginning:

AC Immune SA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on AC Immune SA

Buy the dip entry openings on AC Immune SA

AC Immune SA

The performance achieved by the robo-advisor on AC Immune SA is -0.81%. That represents -2.04$ of latent gain with 251.26$ of employed capital. The following chart shows AC Immune SA stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of AC Immune SA, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-0.81 %

Latent gain

-2.04 $

Invested capital

251.26 $

Annualized return

-0.39 %

Equity curve of the strategy applied to AC Immune SA

The following chart shows the result of the investment strategy applied to AC Immune SA:

AC Immune SA

Note: the dividends potentially given by AC Immune SA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on AC Immune SA

The following chart shows the employed capital evolution since the beginning of the investment strategy on AC Immune SA:

AC Immune SA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on AC Immune SA

In this section, I will compare the three previous investment strategies applied to AC Immune SA.

Equity curve comparison on AC Immune SA

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

AC Immune SA investment strategy comparison

Employed capital comparison on AC Immune SA

AC Immune SA investment comparison

Performance comparison on AC Immune SA

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 8.05% 141.52$ 1756.95$ 1.96%
Momentum 1 quarter 14.33% 752.31$ 5250.96$ 3.71%
Momentum 2 quarters 9.01% 361.06$ 4007.62$ 2.49%
Non-directional -0.81% -2.04$ 251.26$ -0.39%
Annualized return comparison

Automatic investment

1.96 %

Momentum 1Q

2.49 %

Momentum 2Q

2.49 %

Non-directional

-0.39 %

Correlated stocks

Here are the most positively and negatively correlated stocks with AC Immune SA:

Positive correlations

Most correlated stocks this year

  • AC Immune SA

  • Most correlated stocks last 3 months

  • GENSIGHT BIOLOGICS
  • Valhi Inc
  • BURELLE
  • AC Immune SA
  • FAURECIA

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • TCL ELECTRONICS
  • CENTRAL CHINA
  • TRISTEL PLC ORD 1P

  • Note: The algorithm computes the probability of correlation between AC Immune SA and the other stocks. There may be false positives or some missing correlated stocks. If the price of AC Immune SA does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name AC Immune SA
    Country Switzerland
    City Lausanne
    Address Building B
    Phone 41 21 345 91 21
    Website www.acimmune.com
    FullTime employees
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker ACIU
    Market www.nasdaq.com

    AC Immune SA ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown